Double Blind Study to Evaluate the Safety and Efficacy of 400 mg Twice Daily Rifamycin SV MMX® Added to Standard Oral Rehydration Therapy (ORT) Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 12 to 17 Years
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 142
- 主要终点
- Clinical Cure
研究概览
简要总结
This will be a double blind comparative study, performed in pediatric subjects (Age 12-17) traveling to developing regions with a known high incidence of traveler's diarrhea. The subjects will be suffering from acute diarrhea for at least 12 hours, without symptoms of systemic infection.
详细描述
Approximately 142 subjects are expected to be enrolled in the study, 1:1 in the Rifamycin SV MultiMatrix (MMX) plus Oral RehydrationTherapy (ORT) group and in the placebo tablets plus ORT group respectively. The day of randomization (Visit 1, Day 1), the subjects will start the treatment receiving ORT plus Rifamycin SV MMX 400 mg (as two tablets of 200 mg each) twice daily (morning and evening) or ORT plus placebo tablets (as two tablets) twice daily (morning and evening). The subjects will begin the treatment within 72 hours of onset of diarrhea. Treatment duration will last 72 hours. The total number of tablets for the entire treatment course will be 12 (4 × 200 mg tablets/day for 3 days). The administration of the ORT will follow the specification reported in the product label. The tablets will be orally administered during the day. No tablet administration will be done during the night.
After enrollment, subjects/their parents/or guardians will complete Diary Cards (PDC) in which will be daily recorded date, time of first tablets intake, time and consistency of each stool, presence of blood in stools, abdominal pain/cramps, flatulence, tenesmus, urgency, nausea, vomiting, fever, adverse events (AEs), and concomitant medications.
During the study, the subjects will be assessed for safety and efficacy at Visit 2 (Day 2) and Visit 3 (Day 4/5) as final Study Visit.
Stool samples for microbiological assessment will be collected at Visits 1 and 3. Stool will be examined and cultured at local labs for main enteropathogens and for the presence of protozoa, ova and yeasts.
Stool samples will be required in a subset population of the Rifamycin SV MMX group, at the Follow-up visit to determine rifamycin concentration in the feces.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 12 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of acute bacterial diarrhea defined as at least 3 unformed stools within the 24 hours preceding randomization, with a duration of illness ≤72 h. The bacterial origin of diarrhea will be confirmed "a posteriori" by stool microbiology sampling at the time of screening.
- •Presence of one or more signs or symptoms of enteric infection have to be present, including nausea, vomiting, abdominal cramps or pain, tenesmus, urgency
- •History of recent travel from an industrialized country to a developing region with a known high incidence of travelers' diarrhea
- •Male or female 12-17 years of age, providing an unformed pre-treatment stool
- •Females of child-bearing potential must use an acceptable contraceptive method throughout the study treatment period
- •The parent or legally acceptable representative guardian must provide informed consent for the subject. The Subject must also provide written informed assent by the parent or legal guardian at the time of assent/consent signing.
排除标准
- •Fever (>100.4ºF or 38ºC), or presence of signs and symptoms of systemic infection
- •Females pregnant or breast feeding or not using adequate birth control
- •Known or suspected infection with non-bacterial pathogen
- •Symptoms of acute diarrhea of >72 hours duration
- •Presence of grossly bloody stool
- •Moderate to severe dehydration
- •History of inflammatory bowel disease (IBD)
- •Abdominal ileus
- •Severe dehydration
- •Greater than two doses of an antidiarrheal medication within 24 hours before randomization, or any symptomatic therapy within 2 hours before enrolment
- •Receiving antimicrobial drug with expected activity against enteric bacterial pathogens within the week prior to enrolment
- •Hypersensitivity to rifamycin-related antibiotics or to any excipient included in the study medications
- •Subjects unable/unwilling to comply with study protocol
- •Participation in a clinical trial within the last 30 days
研究组 & 干预措施
Rifamycin SV MMX plus ORT
Each tablet contains 200mg Rifamycin SV MMX for oral administration
干预措施: Rifamycin SV MMX (Drug)
Placebo tablets plus ORT
Placebo tablets identical to Rifamycin tablets with respect to size, taste and appearance.
干预措施: Placebo to Rifamycin SV-MMX (Drug)
结局指标
主要结局
Clinical Cure
时间窗: 120 hours
Passage of two or fewer soft stools and no watery stools, no fever (\> 100.4 ºF or 38 ºC), and no signs or symptoms of enteric infection (other than mild excess gas/flatulence) during a 24-hour interval in the 120-hour data collection period after the first dose of study drug or Passage of no stools or only formed stools and no fever during a 48-hour interval in the 120-hour data collection period after the first dose of study drug, with or without other signs or symptoms of enteric infection.
次要结局
- Improvement(24 hours)
- Microbiological Cure(120 hours)
- Time to Last Unformed Stool (TLUS)(120 hours)
- Treatment Failure(120 hours)